Dr. Drilon on Comprehensive Sequencing in Lung Cancer

Video

In Partnership With:

Alexander Drilon, MD, discusses performing comprehensive sequencing in lung cancer.

Alexander Drilon, MD, research director, Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses performing comprehensive sequencing in lung cancer.

There are several actionable genotypes and comprehensive sequencing that identifies all actionable mutations with corresponding targeted therapies must be performed upon diagnosis, explains Drilon. Sequencing has moved past single-gene testing; now, there is one comprehensive test to detect several actionable events, says Drilon.

Next-generation sequencing, which is DNA-based, is readily available in the clinic. However, an RNA-based assay may be necessary to maximize the likelihood of finding a driver, concludes Drilon.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,